Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24494470 | 0.88 | NUDT1 (0.34) | — | |
| SCHEMBL29281914 | 0.88 | DHODH (0.33) | DHODHEIF4EHCAR2CES2CES1 | |
| SCHEMBL29281916 | 0.88 | DHODH (0.33) | DHODHEIF4EHCAR2CES2CES1 | |
| SCHEMBL25207105 | 0.87 | PRKAB2 (0.39) | DHODHFFAR1 | |
| SCHEMBL29281906 | 0.85 | PRKAB2 (0.36) | DHODHFFAR1 | |
| SCHEMBL30318799 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL29281889 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL29281905 | 0.78 | EIF4E (0.33) | DHODHEIF4ECES2CES1KDM4E | |
| SCHEMBL29643184 | 0.77 | KIF11 (0.30) | — | |
| SCHEMBL26167955 | 0.77 | GABRP (0.33) | DHODHEIF4ECES2CES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| CN-117957223-A | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | DHODH 401/4885EIF4E 4390/4885HCAR2 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.